Investor Information

Prana Biotechnology is developing best-in-class therapies to treat neurodegenerative disease.  

The Company's lead drug candidate – PBT2 – is being developed for the treatment of Alzheimer’s and Huntington diseases. The Company is targeting lodgement of a New Drug Application for Huntington's disease in 2016/2017 pending positive trial results.

The Company was incorporated in 1997 in Melbourne, Australia and listed on the Australian Securities Exchange in 2000 (ASX: PBT) and NASDAQ in 2002 (NASDAQ: PRAN).

Governance Documents

Analysts covering ASX.PBT / NASDAQ.PRAN

MLV & Co

George Zavoico
+1 203 542 5877

Wilson HTM

Shane Storey
+61 7 3212 1351

ASX Announcements

Financial Reports

Archived Reports